Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone in Heart Failure with LVEF ≥ 40%
NCT04435626Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 37
01
Overview
A Phase 3 trial of finerenone in heart failure (HF), sponsored by Bayer. Started Sep 2020; status: completed.
02
Drugs
finerenone
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04435626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04435626.